| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA151067
Max Phase: Preclinical
Molecular Formula: C20H15ClFN3O2S
Molecular Weight: 415.88
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OCc1ccsc1
Standard InChI: InChI=1S/C20H15ClFN3O2S/c1-26-18-7-14-17(8-19(18)27-9-12-4-5-28-10-12)23-11-24-20(14)25-16-3-2-13(21)6-15(16)22/h2-8,10-11H,9H2,1H3,(H,23,24,25)
Standard InChI Key: ORADRWKXLYIOGS-UHFFFAOYSA-N
Associated Targets(Human)
Vascular endothelial growth factor receptor 1 6262 Activities
Vascular endothelial growth factor receptor 2 20924 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Fibroblast growth factor receptor 1 9149 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
VEGF-receptor 2 and Fibroblast growth factor receptor 1 50 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 415.88 | Molecular Weight (Monoisotopic): 415.0558 | AlogP: 5.82 | #Rotatable Bonds: 6 |
| Polar Surface Area: 56.27 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 1 |
| #RO5 Violations: 1 | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: | CX Basic pKa: 4.46 | CX LogP: 5.40 | CX LogD: 5.40 |
| Aromatic Rings: 4 | Heavy Atoms: 28 | QED Weighted: 0.43 | Np Likeness Score: -1.93 |
References
| 1. Hennequin LF, Thomas AP, Johnstone C, Stokes ES, Plé PA, Lohmann JJ, Ogilvie DJ, Dukes M, Wedge SR, Curwen JO, Kendrew J, Lambert-van der Brempt C.. (1999) Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors., 42 (26): [PMID:10639280] [10.1021/jm990345w] |
Source
Source(1):